Micromet
Boehringer signs antibody myeloma R&D deal
May 10, 2010Research and Development Boehringer, Cancer, Micromet, myeloma
Boehringer Ingelheim and US biotech company Micromet are to research and develop a new BiTE antibody to treat multiple myeloma. …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
